Programme

Module 1 – FROM DISCOVERY TO PATENT TO BIOTECH COMPANY
29/10/09	Speaker	Timing
Welcome and introduction IFB-Masterclass	Martine Wouters Peter Raeymaekers	9.00-9.30 coffee 9.30-10.15
Biopharmaceutical drug development between academia and industry – a case study How to optimize the interaction between academia and industry? The role of biomedical research institutes in licensing proprietary know-how into dedicated  biopharmaceutical spin-offs A case study of such an interaction between the K.U.Leuven, VIB and the biopharmaceutical spin-off ThromboGenics NV  Relative roles of intellectual property, licensing arrangements, contract research and translational research in selected areas of biopharmaceutical medicine.	Désiré Collen Founder and chairman ThromboGenics	10.15-11.00 break 11.30-12.30
Lunch		12.30 - 13.30
The legislator’s view Coordination and fine tuning of legislation: Europe, Belgium and the regions.   Governmental sources of financing. Healthy tension or collision between industry and politics, health vs employment Politics and industry, even up to the court room. A good matter?	Patrick Van Krunkelsven Senator Open Vld	13.30-15.30
The biotech business: overview, impact, next generation … making the revolution visible The invisible revolution made visible How does policy influence entrepreneurship?  Policy intended to welcome R&D & Innovation Mobilise Member states to Defrag Europe? Biotech needs the community patent, where is it?	Johan Van Hemelrijck Health Care Manager Bio.Be Former Secretary General EuropaBio	16.00-17.30
Who is Who: start of networking		19.00 apero & dinner
30/10/09
IP-management, managing your most important assets What types of IP rights are crucial in the biotechiotech industry? Which variety of options and actions should you bear in mind? (contracts, strategy, valuation, litigation) How can you adjust IP lifecycles to your companies' lifecycles?  Which other interactions of IP rights with other rights should you manage?  An example: biotech pharma company life cycle litigation	Liesbeth Weynants Intellectual Property, Public & Regulatory, Dispute Resolution, Nauta Dutilh, Brussels	09.00-10.30 break 11.00-12.30
Lunch		12.30-13.30
Ingredients for start-ups from knowledge institutes A journey in the transcription of an invention in a business plan The translation of a business plan in a start-up	Rudy Dekeyser Managing Director,      Vlaams Instituut voor Biotechnologie	13.30-15.00 break 15.30-16.30

Module 2 – HOW TO BECOME AN ESTABLISHED LIFE SCIENCE COMPANY
26/11/09	Speaker	Timing
IP-management, part II	Frank Landolt IP and Legal Counsel,  Ablynx	9.30-11.00 break 11.30-12.30
Lunch		12.30-13.30
Financial Management: basics for shareholder value creation How to interpret the major financial dash-boards: balance sheet, profit & loss and cash-flow statements? How to create and evaluate shareholder value? The budget process: threat or opportunity? The legal framework and the standards: how and what for? Corporate governance	Jean-Paul Blondeel Senior Director Finance & IT,  Innovex – Quintiles	13.30-15.00 break 15.30-17.00
European regulatory aspects for a red biotech company Basic EU legislative framework for development of biotech products, from laboratory to market EU Marketing authorisation procedures: the application, the assessment , the decision, post marketing requirements	Carla Schoonderbeek Public & Regulatory, Partner Nauta Dutilh, Amsterdam	19.00 apero & dinner
27/11/09
Daily life at big biotech: what is different? National regulatory aspects: pricing and reimbursement for red biotech companies What is the 4th hurdle? What needs to be considered during product development?	Annie Hubert Corporate Affairs Director of Amgen’s affiliate in Belgium and Luxembourg Chris Van Den Broucke Vice President and Regional Director Amgen International	9.00-10.30 break 11.00-12.30
Lunch
Corporate communications: from issue to crisis management Issue management as underlying framework for dealing with the media Risk perception as underlying framework for crisis management Science and the media: why clever people believe stupid things	Johan De Rycker Director Corporate & Public Affairs, Raffinerie Tirlemontoise and ULB Professor in communication	13.30-15.00 break 15.30-16.30

Module 3 - CRUCIAL FOR SUCCESS: FINANCING AND DEAL MAKING
04/02/10	Speaker	Timing
Venture capitalists: partners for the growth of your company How to get financing in this difficult environment? Investment criteria What are VCs looking for? What not? What has changed/is changing? How to get an exit for investors/shareholders? Some cases: Devgen, Ablynx, ActoGeniX,…	Patrick Van Beneden Executive Vice President Life Sciences, GIMV	9.00-10.30 break 11.00-12.30
Lunch
Deal making from a biotech’s company’s perspective	Eva Lotta Allen Chief Business Officer,  Ablynx	13.30-15.00 break 15.30-17.00
The future of Europe	Jean-Luc Dehaene Member of the European Parliament for CD&V	19.00 apero & dinner
05/02/10
Negotiation Skills: Crafting the Deal What can you do to increase your ability to negotiate deals to influence peers to persuade investors to avoid needless conflict to improve financial terms and influence decisions of business partners?	Dirk Van Poucke Professor ‘Negotiation, competitive decision making and conflict management’	9.00-16.30

Module 4 - EXIT STRATEGY, PRODUCTS ON THE MARKET AND THE FUTURE
04/03/10	Speaker	Timing
Ways to grow or exit?  Mergers & Acquisitions Being taken over IPO	Herman Spolders Founder and Chief Executive Officer of OncoMethylome Sciences	9.00-10.30 break 11.00h-12.30
Lunch		12.30 - 13.30
The role of the EMEA in fostering innovative medicines en route for marketing authorisation Who is Who and what is what (different comities, working parties, CAT,…) at EMEA  Real-life examples. How should a ‘good’ dossier look like Challenges, pitfalls  EMEA-FDA relationship What brings the future (regarding registration)	Bruno Flamion Chair of Scientific Advice Working Party, European Medicines Agency (EMEA)	13.30-15.00 break 15.30-17.00
Gala dinner		18.30
05/03/10
How to win the war on talent? How to bring people with knowledge and talent tot your company  ‘THE’ Employee?…  Employment Value Proposition  Communication and Trust are key  Example of a ‘Good Practice’: BREATH  Measuring Effectiveness	Ann Dhoore Human Resources Senior Manager at Amgen Belux & Amgen Netherlands Affiliate	9.00-10.30 break 11.00-12.30
Lunch		12.30 - 13.30
Towards an integrated life science sector	Paul Stoffels Company Group Chairman, Global Research and Development, Pharmaceuticals Group, Johnson and Johnson*	13.30-15.00 break 15.30-16.15
Closing Remarks		16.15-16.30

* Paul Stoffels has confirmed his participation but in case of urgency there will be a back up from Johnson and Johnson.